Development of a Candidate TMV Epitope Display Vaccine against SARS-CoV-2
Vaccines · 23.04.2024 · 12 (5) · 448
DOI: 10.3390/vaccines12050448 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 23.04.2024. Verfasst von Kelvin Phiri und 1 weiteren Autor:innen. Beteiligte Einrichtung: Henry E. Riggs School of Applied Life Sciences, Keck Graduate Institute, Claremont, CA 91711, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gift from Dr S Glanville, Dr. R. Steven Glanville, Dr. Linda Glanville.
Abstract (Originalsprache)
Essential in halting the COVID-19 pandemic caused by SARS-CoV-2, it is crucial to have stable, effective, and easy-to-manufacture vaccines. We developed a potential vaccine using a tobacco mosaic virus (TMV) epitope display model presenting peptides derived from the SARS-CoV-2 spike protein. The TMV-epitope fusions in laboratory tests demonstrated binding to the SARS-CoV-2 polyclonal antibodies. The fusion constructs maintained critical epitopes of the SARS-CoV-2 spike protein, and two in particular spanned regions of the receptor-binding domain that have mutated in the more recent SARS-CoV-2 variants. This would allow for the rapid modification of vaccines in response to changes in circulating variants. The TMV-peptide fusion constructs also remained stable for over 28 days when stored at temperatures between −20 and 37 °C, an ideal property when targeting developing countries. Immunogenicity studies conducted on BALB/c mice elicited robust antibody responses against SARS-CoV-2. A strong IFNγ response was also observed in immunized mice. Three of the six TMV-peptide fusion constructs produced virus-neutralizing titers, as measured with a pseudovirus neutralization assay. These TMV-peptide fusion constructs can be combined to make a multivalent vaccine that could be adapted to meet changing virus variants. These findings demonstrate the development of a stable COVID-19 vaccine candidate by combining SARS-CoV-2 spike protein-derived peptides presented on the surface of a TMV nanoparticle.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Henry E. Riggs School of Applied Life Sciences, Keck Graduate Institute, Claremont, CA 91711, USA.
ORCID-Profile: Kelvin Phiri
Förderung
- Gift from Dr S Glanville
- Dr. R. Steven Glanville
- Dr. Linda Glanville
Zitieren
APA
Phiri, K., & Grill, L. (2024). Development of a Candidate TMV Epitope Display Vaccine against SARS-CoV-2. Vaccines, 12(5), 448. https://doi.org/10.3390/vaccines12050448
Vancouver
Phiri K, Grill L. Development of a Candidate TMV Epitope Display Vaccine against SARS-CoV-2. Vaccines. 2024;12(5):448. doi:10.3390/vaccines12050448
BibTeX
@article{Phiri2024,
author = {Phiri, Kelvin and Grill, Larry},
title = {Development of a Candidate TMV Epitope Display Vaccine against SARS-CoV-2},
journal = {Vaccines},
year = {2024},
volume = {12},
number = {5},
pages = {448},
doi = {10.3390/vaccines12050448}
}
EUVIMED